IL17A and myasthenia gravis: By the 12-week mark, the difference in the levels of the IL-17 (6.5 pg/mL vs 3.8 pg/mL, p = 0.010), IL-21 (8.4 pg/mL vs 4.4 pg/mL, p = 0.010) in MG patients and HCs were further reduced (Figures 6A, B).